Adoption of a clinical pharmacogenomics implementation program during outpatient care–initial results of the University of Chicago "1, 200 Patients Project". Issue 1 (10th March 2014)

• Record Type: Journal Article
• Authors: O'Donnell, Peter H.; Danahey, Keith; Jacobs, Michael; Wadhwa, Nisha R.; Yuen, Shennin; Bush, Angela; Sacro, Yasmin; Sorrentino, Matthew J.; Siegler, Mark; Harper, William; Warrick, Andrea; Das, Soma; Saner, Don; Corless, Christopher L.; Ratain, Mark J.; Williams, Marc S.
• Is Part Of: American journal of medical genetics. Volume 166:Issue 1(2014)
• Page Start: 68
• Page End: 75
• Publication Date: 2014-03-10
• Subjects: Medical genetics -- Periodicals; 616.04205
• DOI: 10.1002/ajmg.c.31385
• Languages: English
• ISSNs: 1552-4868

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="ajmgc31385-sec-0001" sec-type="section"> <p>Pharmacogenomic testing is viewed as an integral part of precision medicine. To achieve this, we originated The 1, 200 Patients Project which offers broad, preemptive pharmacogenomic testing to patients at our institution. We analyzed enrollment, genotype, and encounter‐level data from the first year of implementation to assess utility of providing pharmacogenomic results. Results were delivered via a genomic prescribing system (GPS) in the form of traffic lights: green (favorable), yellow (caution), and red (high risk). Additional supporting information was provided as a virtual pharmacogenomic consult, including citation to relevant publications. Currently, 812 patients have participated, representing 90% of those approached; 608 have been successfully genotyped across a custom array. A total of 268 clinic encounters have occurred at which results were accessible via the GPS. At 86% of visits, physicians accessed the GPS, receiving 367 result signals for medications patients were taking: 57% green lights, 41% yellow lights, and 1.4% red lights. Physician click frequencies to obtain clinical details about alerts varied according to color severity (100% of red were clicked, 72% yellow, 20% green). For 85% of visits, clinical pharmacogenomic information was available for at least one drug the patient was taking, suggesting relevance of the delivered information. We successfully implemented an individualized health care model of preemptive pharmacogenomic testing, delivering results along with pharmacogenomic decision support. Patient interest was robust, physician adoption of information was high, and results were routinely utilized. Ongoing examination of a larger number of clinic encounters and inclusion of more physicians and patients is warranted. © 2014 Wiley Periodicals, Inc.</p> </sec> </abstract>